Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts

Gynecologic Oncology 2026

View at publisher
Authors: Luca Palmieri, Stefania Bellone, Cem Demirkiran, Tobias MP Hartwich, Namrata Sethi, Victoria M. Ettorre, Sarah Ottum, Michelle Greenman, Natalia Buza, Pei Hui, Emanuele Perrone, Francesco Fanfani
+3 more Anna Fagotti, Elena Ratner, Alessandro D. Santin
DOI: 10.1016/j.ygyno.2026.02.004
Cited by: 4
References: 40

Fields of Study & Subjects

HER2/EGFR in Cancer Research Endometrial and Cervical Cancer Treatments Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
Gynecologic Oncology
Publisher
Elsevier BV
Volume
206
Pages
65–73
Publication date
13 February 2026
Language
EN